Amol K Narang1, Alexi A Wright2, Lauren H Nicholas3. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts3Harvard Medical School, Boston, Massachusetts. 3. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland5Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
Abstract
IMPORTANCE: Advance care planning (ACP) may prevent end-of-life (EOL) care that is nonbeneficial and discordant with patient wishes. Despite long-standing recognition of the merits of ACP in oncology, it is unclear whether participation in ACP by patients with cancer has increased over time. OBJECTIVES: To characterize trends in durable power of attorney (DPOA) assignment, living will creation, and participation in discussions of EOL care preferences and to explore associations between ACP subtypes and EOL treatment intensity as reflected in EOL care decisions and terminal hospitalizations. DESIGN, SETTING, AND PARTICIPANTS: We analyzed prospectively collected survey data from 1985 next-of-kin surrogates of Health and Retirement Study (HRS) participants with cancer who died between 2000 and 2012, including data from in-depth "exit" interviews conducted with the surrogates after the participant's death. The HRS is a nationally representative, biennial, longitudinal panel study of US residents older than 50 years. Trends in ACP subtypes were tested, and multivariable logistic regression models examined for associations between ACP subtypes and measures of treatment intensity. MAIN OUTCOMES AND MEASURES: Trends in the surrogate-reported frequency of DPOA assignment, living will creation, and participation in discussions of EOL care preferences; associations between ACP subtypes and both surrogate-reported EOL care decisions and terminal hospitalizations. RESULTS: From 2000 to 2012, there was an increase in DPOA assignment (52% to 74%, P = .03), without significant change in use of living wills (49% to 40%, P = .63) or EOL discussions (68% to 60%, P = .62). Surrogate reports that patients received "all care possible" at EOL increased during the period (7% to 58%, P = .004), and rates of terminal hospitalizations were unchanged (29% to 27%, P = .70). Limiting or withholding treatment was associated with living wills (adjusted odds ratio [AOR], 2.51; 95% CI, 1.53-4.11; P < .001) and EOL discussions (AOR, 1.93; 95% CI, 1.53-3.14; P = .002) but not with DPOA assignment. CONCLUSIONS AND RELEVANCE: Use of DPOA increased significantly between 2000 and 2012 but was not associated with EOL care decisions. Importantly, there was no growth in key ACP domains such as discussions of care preferences. Efforts that bolster communication of EOL care preferences and also incorporate surrogate decision makers are critically needed to ensure receipt of goal-concordant care.
IMPORTANCE: Advance care planning (ACP) may prevent end-of-life (EOL) care that is nonbeneficial and discordant with patient wishes. Despite long-standing recognition of the merits of ACP in oncology, it is unclear whether participation in ACP by patients with cancer has increased over time. OBJECTIVES: To characterize trends in durable power of attorney (DPOA) assignment, living will creation, and participation in discussions of EOL care preferences and to explore associations between ACP subtypes and EOL treatment intensity as reflected in EOL care decisions and terminal hospitalizations. DESIGN, SETTING, AND PARTICIPANTS: We analyzed prospectively collected survey data from 1985 next-of-kin surrogates of Health and Retirement Study (HRS) participants with cancer who died between 2000 and 2012, including data from in-depth "exit" interviews conducted with the surrogates after the participant's death. The HRS is a nationally representative, biennial, longitudinal panel study of US residents older than 50 years. Trends in ACP subtypes were tested, and multivariable logistic regression models examined for associations between ACP subtypes and measures of treatment intensity. MAIN OUTCOMES AND MEASURES: Trends in the surrogate-reported frequency of DPOA assignment, living will creation, and participation in discussions of EOL care preferences; associations between ACP subtypes and both surrogate-reported EOL care decisions and terminal hospitalizations. RESULTS: From 2000 to 2012, there was an increase in DPOA assignment (52% to 74%, P = .03), without significant change in use of living wills (49% to 40%, P = .63) or EOL discussions (68% to 60%, P = .62). Surrogate reports that patients received "all care possible" at EOL increased during the period (7% to 58%, P = .004), and rates of terminal hospitalizations were unchanged (29% to 27%, P = .70). Limiting or withholding treatment was associated with living wills (adjusted odds ratio [AOR], 2.51; 95% CI, 1.53-4.11; P < .001) and EOL discussions (AOR, 1.93; 95% CI, 1.53-3.14; P = .002) but not with DPOA assignment. CONCLUSIONS AND RELEVANCE: Use of DPOA increased significantly between 2000 and 2012 but was not associated with EOL care decisions. Importantly, there was no growth in key ACP domains such as discussions of care preferences. Efforts that bolster communication of EOL care preferences and also incorporate surrogate decision makers are critically needed to ensure receipt of goal-concordant care.
Authors: Gabriel A Brooks; Ling Li; Dhruv B Sharma; Jane C Weeks; Michael J Hassett; K Robin Yabroff; Deborah Schrag Journal: J Natl Cancer Inst Date: 2013-03-12 Impact factor: 13.506
Authors: Sangeeta C Ahluwalia; Fukai L Chuang; Anna Liza M Antonio; Jennifer L Malin; Karl A Lorenz; Anne M Walling Journal: J Oncol Pract Date: 2011-11 Impact factor: 3.840
Authors: Amanda Sonnega; Jessica D Faul; Mary Beth Ofstedal; Kenneth M Langa; John W R Phillips; David R Weir Journal: Int J Epidemiol Date: 2014-03-25 Impact factor: 7.196
Authors: Michael H Levy; Thomas Smith; Amy Alvarez-Perez; Anthony Back; Justin N Baker; Susan Block; Shirley N Codada; Shalini Dalal; Maria Dans; Jean S Kutner; Elizabeth Kvale; Sumathi Misra; William Mitchell; Todd M Sauer; David Spiegel; Linda Sutton; Robert M Taylor; Jennifer Temel; Roma Tickoo; Susan G Urba; Carin Van Zyl; Sharon M Weinstein; Mary Anne Bergman; Jillian L Scavone Journal: J Natl Compr Canc Netw Date: 2014-10 Impact factor: 11.908
Authors: Elizabeth K Vig; Helene Starks; Janelle S Taylor; Elizabeth K Hopley; Kelly Fryer-Edwards Journal: J Gen Intern Med Date: 2007-07-07 Impact factor: 5.128
Authors: Rajiv Agarwal; Elyse Shuk; Danielle Romano; Margaux Genoff; Yuelin Li; Eileen M O'Reilly; William Breitbart; Angelo E Volandes; Andrew S Epstein Journal: Support Care Cancer Date: 2019-06-13 Impact factor: 3.603
Authors: Andrew S Epstein; Anjali V Desai; Camila Bernal; Danielle Romano; Peter J Wan; Molly Okpako; Kelly Anderson; Kimberly Chow; Dana Kramer; Claudia Calderon; Virginia V Klimek; Robin Rawlins-Duell; Diane L Reidy; Jessica I Goldberg; Elizabeth Cruz; Judith E Nelson Journal: J Pain Symptom Manage Date: 2019-04-26 Impact factor: 3.612
Authors: Anna Kata; Irena Cenzer; Rebecca L Sudore; Kenneth E Covinsky; Victoria L Tang Journal: J Gen Intern Med Date: 2020-05-04 Impact factor: 5.128
Authors: Gabrielle B Rocque; J Nicholas Dionne-Odom; Chao-Hui Sylvia Huang; Soumya J Niranjan; Courtney P Williams; Bradford E Jackson; Karina I Halilova; Kelly M Kenzik; Kerri S Bevis; Audrey S Wallace; Nedra Lisovicz; Richard A Taylor; Maria Pisu; Edward E Partridge; Thomas W Butler; Linda A Briggs; Elizabeth A Kvale Journal: J Pain Symptom Manage Date: 2017-01-03 Impact factor: 3.612
Authors: Bobby Daly; Andrew Hantel; Kristen Wroblewski; Jay S Balachandran; Selina Chow; Rebecca DeBoer; Gini F Fleming; Olwen M Hahn; Justin Kline; Hongtao Liu; Bhakti K Patel; Anshu Verma; Leah J Witt; Mayumi Fukui; Aditi Kumar; Michael D Howell; Blase N Polite Journal: J Oncol Pract Date: 2016-10 Impact factor: 3.840